| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00324324 Details | 2017-05-09 Interventional | 3 | [1 Refs] | - | Moxifloxacin Norgestimate, e… Bacterial Infec… Breast Neoplasm… Communicable Di… Infections Leukemia Lymphoma Multiple Myelom… Myelodysplastic… Myelodysplastic… Myeloproliferat… Neoplasms Neoplasms, Germ… Neoplasms, Plas… Neuroblastoma Plasmacytoma Preleukemia Syndrome Trophoblastic N… Breast Cancer Chronic Myelopr… Gestational Tro… Infection Multiple Myelom… Myelodysplastic… Ovarian Cancer Testicular Germ… | - - | ||
| NCT00140920 Details | 2017-05-09 Interventional | 4 | 11 | Diclofenac Rofecoxib Pain, Postopera… Pain | Recruitment/study discontinued after withdrawal of marketing authorisation. No data entered. - | |||
| NCT02213029 Details | 2017-05-08 Interventional | 1 | 33 | Oxytocin Embryo Transfer | - - | |||
| NCT00915590 Details | 2017-05-08 Interventional | 1/2 | 10 | Interleukin 1 R… Corneal Neovasc… Neovascularizat… | - Enrollment goal for this study was set at 20 participants (10 for each treatment arm). After an interim analysis, the Principal Investigator decided to terminate the study and stop enrollment. | |||
| NCT02544269 2015-003498-13 Details | 2017-05-05 Interventional | 4 | 8 | Bupivacaine Ropivacaine Total Hip Repla… | After pilot study no difference in the primary end point was found between the two primary.
Non-inferiority trial not deemed feasible. - | |||
| NCT02428231 2014-004562-22 Details | 2017-05-05 Interventional | 3 | 62 | Dimethyl Fumara… Multiple Sclero… Sclerosis | Sponsor decision The Sponsor decided to terminate the study as a result of an evaluation of ongoing development programs. | |||
| NCT02368249 Details | 2017-05-05 Interventional | 2 | 0 | Terlipressin Renal Insuffici… Kidney Failure | no focus on this topic - | |||
| NCT01937364 Details | 2017-05-05 Interventional | 2 | 17 | Baclofen Alcoholism Alcohol Withdra… | The enrollment in the study was too limited for meaningful data analysis. - | |||
| NCT01353378 Details | 2017-05-05 Interventional | 4 | 0 | Dexmedetomidine Delirium Emergence Delir… | The study was not approved by Hospital's Medical Ethics Committee. - | |||
| NCT02516436 Details | 2017-05-04 Interventional | 3 | 0 | Buprenorphine Opioid-Related … Opioid Dependen… | FDA did not require a clinical trial for indication. - | |||
| NCT01713803 Details | 2017-05-04 Interventional | 3 | 0 | Buprenorphine Naloxone Opioid-Related … Opioid Dependen… | FDA did not require a clinical trial for indication. - | |||
| NCT02791919 Details | 2017-05-03 Interventional | 1 | 0 | Adavosertib Cytarabine Fludarabine Fludarabine pho… Lenograstim Leukemia Leukemia, Myelo… Leukemia, Myelo… Recurrence CNS 2a CNS 2b CNS 2c CNS1 Recurrent Adult… Recurrent Child… | Other - Protocol moved to Disapproved - | |||
| NCT02753218 Details | 2017-05-03 Interventional | 1 | 12 | Midazolam Psoriasis Psoriasis Vulga… | Due to tolerability issues related to the dose titration, unexpected withdrawals were observed
and it was unlikely for the trial to meet its objectives - | |||
| NCT02359500 Details | 2017-05-03 Interventional | 1 | 71 | Edotreotide Octreotide Carcinoid Tumor Neoplasms Neuroendocrine … Carcinoid Tumor… | compound no longer available - | |||
| NCT02206776 Details | 2017-05-03 Interventional | 2 | 2 | Ketamine Midazolam Compulsive Pers… Obsessive-Compu… | poor tolerability and low enrollment rate - | |||
| NCT01379521 Details | 2017-05-03 Interventional | 2 | 65 | Everolimus Carcinoma Carcinoma, Hepa… Hepatocellular … | The study was terminated due to low enrollment. This resulted in the study being underpowered
and inconclusive. - | |||
| NCT01002339 Details | 2017-05-03 Interventional | 4 | [1 Refs] | 134 | Basiliximab Cyclosporine Mycophenolic Ac… Prednisone Tacrolimus Diabetes Mellit… Diabetes Mellit… Diabetes Mellit… | Terminated: higher rate of acute rejection in the Cyclosporin A group - | ||
| NCT02227914 2014-003149-85 Details | 2017-05-02 Interventional | 1/2 | 0 | Sorafenib Carcinoma Carcinoma, Hepa… Advanced Hepato… | Study stopped due to administrative reasons - | |||
| NCT00974675 2006-003199-36 Details | 2017-05-02 Interventional | 1 | 23 | Antibodies, Mon… Asthma Moderate Asthma | Study recruitment was terminated before the planned number of subjects was enrolled in CAT-354
10 mg/kg group due to the slow recruitment rate. Recruitment to the study was terminated before the planned number of participants was enrolled in CAT-354 10 mg/kg group due to the slow recruitment rate. | |||
| NCT02614586 Details | 2017-05-01 Interventional | 1 | 11 | Ondansetron Schizophrenia | - - |